Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2024 Mar 27

PMID 38534959

Authors

Simon Nannini

Florian Guisier

Hubert Curcio

Charles Ricordel

Pierre Demontrond

Safa Abdallahoui

Seyyid Baloglu

Laurent Greillier

Christos Chouaid

Roland Schott

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25/31). Among 38/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.

References

Brastianos P, Kim A, Giobbie-Hurder A, Lee E, Lin N, Overmoyer B . Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nat Med. 2023; 29(7):1728-1737. PMC: 10644912. DOI: 10.1038/s41591-023-02392-7. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R . Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-1177. PMC: 4916970. DOI: 10.1158/2159-8290.CD-15-0369. View

Sperduto P, Mesko S, Li J, Cagney D, Aizer A, Lin N . Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020; 38(32):3773-3784. PMC: 7655019. DOI: 10.1200/JCO.20.01255. View

Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F . EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021; 32(11):1332-1347. DOI: 10.1016/j.annonc.2021.07.016. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Goldberg S, Schalper K, Gettinger S, Mahajan A, Herbst R, Chiang A . Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020; 21(5):655-663. PMC: 7380514. DOI: 10.1016/S1470-2045(20)30111-X. View

Arvanitis C, Ferraro G, Jain R . The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2019; 20(1):26-41. PMC: 8246629. DOI: 10.1038/s41568-019-0205-x. View

Powell S, Rodriguez-Abreu D, Langer C, Tafreshi A, Paz-Ares L, Kopp H . Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021; 16(11):1883-1892. DOI: 10.1016/j.jtho.2021.06.020. View

10.

Eguren-Santamaria I, Sanmamed M, Goldberg S, Kluger H, Idoate M, Lu B . PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clin Cancer Res. 2020; 26(16):4186-4197. DOI: 10.1158/1078-0432.CCR-20-0798. View

11.

Nieder C, Guckenberger M, Gaspar L, Rusthoven C, De Ruysscher D, Sahgal A . Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiat Oncol. 2019; 14(1):33. PMC: 6377775. DOI: 10.1186/s13014-019-1237-9. View

12.

Goldberg S, Gettinger S, Mahajan A, Chiang A, Herbst R, Sznol M . Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17(7):976-983. PMC: 5526047. DOI: 10.1016/S1470-2045(16)30053-5. View

13.

Waqar S, Samson P, Robinson C, Bradley J, Devarakonda S, Du L . Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin Lung Cancer. 2018; 19(4):e373-e379. PMC: 6990432. DOI: 10.1016/j.cllc.2018.01.007. View

14.

Abid H, Watthanasuntorn K, Shah O, Gnanajothy R . Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier. Cureus. 2019; 11(4):e4446. PMC: 6559690. DOI: 10.7759/cureus.4446. View

15.

de Alencar V, Camandaroba M, Pirolli R, Fogassa C, Cordeiro de Lima V . Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study. J Thorac Oncol. 2021; 16(8):1379-1391. DOI: 10.1016/j.jtho.2021.04.014. View

16.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

17.

Masson F, Calzascia T, di Berardino-Besson W, De Tribolet N, Dietrich P, Walker P . Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 2007; 179(2):845-53. DOI: 10.4049/jimmunol.179.2.845. View

18.

Fischer G, Jalali A, Kircher D, Lee W, McQuade J, Haydu L . Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019; 9(5):628-645. PMC: 6497554. DOI: 10.1158/2159-8290.CD-18-1489. View

19.

Patel R, Verma V, Miller A, Lin T, Jethanandani A, Espinoza A . Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol. 2020; 22(4):577-579. PMC: 7158639. DOI: 10.1093/neuonc/noz246. View

20.

Kim N, Kim H, Lee K, Hong Y, Cho J, Choi J . Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020; 11(1):2285. PMC: 7210975. DOI: 10.1038/s41467-020-16164-1. View